Clinical results indicated that indoximod exerted little antitumor efficacy as a single agent, but efficacy was markedly enhanced when it was combined with other therapies, such as PD-1 checkpoint inhibitors (in advanced melanoma), cancer vaccines (in metastatic prostate cancer), and chemotherapy (in pancreatic cancer and acute myeloid leukemia). The gene discussed is PDCD1; the disease is cancer.